Get a free sample of Antisense and RNAi Therapeutics Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Antisense and RNAi Therapeutics Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Antisense and RNAi Therapeutics Market Size
Antisense And RNAi Therapeutics Market size was valued at USD 4.4 billion in 2023 and is anticipated to showcase growth at 18.2% CAGR from 2024 and 2032. Increasing prevalence of neurodegenerative and genetic disorders, growing investments in research related to gene expression and delivery technologies, growth in regulatory approvals for RNAi and antisense therapeutics is driving the market.
Additionally, rising awareness towards RNA-based therapeutics is also adding to the revenue growth in the market. Initiatives from patient advocacy groups and campaigns to raise disease awareness are advocating access to innovative treatments and expediting their integration into clinical practice thereby contributing to rise in awareness for advanced RNA-based therapies.
Antisense therapy utilizes short synthetic nucleic acid sequences known as antisense oligonucleotides to selectively target and regulate the expression of genes responsible for diseases. RNA interference is an intrinsic cellular mechanism that controls gene expression. In this process, small RNA molecules like small interfering RNAs (siRNAs) or microRNAs (miRNAs) hinder the translation or trigger the degradation of particular mRNA molecules.
Who are the major global antisense and RNAi therapeutics industry players?
Alnylam Pharmaceuticals, Inc, Arbutus Biopharma, Arrowhead Pharmaceuticals, Inc, Benitec Biopharma Inc, BioNTech SE, CRISPR Therapeutics, GlaxoSmithKline plc, Ionis Pharmaceuticals, Inc, Novartis AG, OliX Pharmaceuticals, Inc, Orna Therapeutics, Inc, and Percheron Therapeutics Ltd.
Why is the antisense and RNAi therapeutics industry booming in North America?
North America antisense and RNAi therapeutics market accounted for 42.1% share in 2023 and is predicted to reach USD 8.2 billion by 2032, driven by the presence of large number of pharmaceutical manufacturers in the country offering advanced treatment options.
Why is the demand for RNA interference antisense and RNAi therapeutics rising?
The RNA interference technology segment in the market held 62.4% share in 2023 and will expand rapidly through 2032, owing to its broader application spectrum compared to antisense RNA, making it more versatile and applicable.
How much is the global antisense and RNAi therapeutics industry worth?
The antisense and RNAi therapeutics market size was valued at USD 4.4 billion in 2023 and will register 18.2% CAGR from 2024